ABUS Arbutus Biopharma Corporation - Fundamental Analysis

BEARISH

ABUS Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$4.27

Analyst Target

$5.75

+34.6% Upside

52W High

$5.1

52W Low

$2.71

Overview AI Snowflake Price Valuation Profitability Growth Health Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Feb 21, 2026

Market cap

$821.22M

P/E

N/A

ROE

-45.9%

Profit margin

-289.4%

Debt/Equity

0.06

Dividend yield

N/A

AI Analysis

Confidence Score

85%

Analysis Accuracy

ABUS exhibits severe financial distress signals, with a Piotroski F-Score of 0/9 indicating extreme operational and financial weakness. The company reports massive negative margins, declining revenue, and unprofitable operations, while its Altman Z-Score is unavailable—raising red flags for potential distress. Despite a strong recent price performance, the valuation multiples are inflated relative to fundamentals, and the lack of any dividend or insider buying undermines investor confidence. The stock trades at a Price/Sales of 56.23 and Forward P/E of -25.47, suggesting speculative pricing based on future hope rather than current value. Analysts offer a target of $5.75, but with no consensus recommendation and a weak earnings track record, the upside is highly uncertain.

Key Strengths

Recent 1-month price surge of +7.3% indicates short-term momentum

High insider sentiment score of 40/100 suggests some internal confidence

Extremely low debt/equity ratio of 0.06 implies minimal financial leverage risk

Strong current and quick ratios (18.80 and 18.31) indicate robust short-term liquidity

Positive earnings surprise in Q1 2025 (115.2%) shows potential for upside volatility

Key Risks

Piotroski F-Score of 0/9 signals severe financial deterioration and operational failure

Negative profit margins (Gross: -98.86%, Operating: -1567.67%) indicate unsustainable business model

Revenue declined 60.5% YoY, reflecting deteriorating core business performance

No analyst consensus or target price data available, indicating low institutional interest

Forward P/E of -25.47 and Price/Sales of 56.23 suggest extreme overvaluation relative to earnings and sales

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk

Key drivers: Piotroski F-Score of 0/9, Negative profitability across all metrics, 60.5% YoY revenue decline, No analyst consensus, Extremely high valuation multiples

Confidence

90%

Value

10/100

Valuation is severely inflated; no defensive fair value exists. Stock trades at a premium due to speculative growth expectations, not fundamentals.

Positives

Low debt/equity ratio (0.06)
High current and quick ratios (18.80, 18.31)

Watchpoints

Price/Sales of 56.23 (extremely high)
Forward P/E of -25.47 (negative, unprofitable)
No Graham Number or intrinsic value available

Future

30/100

Future outlook is highly uncertain. While there are isolated positive surprises, the underlying business is contracting rapidly.

Positives

Recent positive earnings surprise (115.2%) in Q1 2025
Some quarterly EPS growth (57.1% YoY)
1-month price increase of +7.3%

Watchpoints

Revenue down 60.5% YoY
Q/Q EPS growth of -700.0%
No clear path to profitability

Past

20/100

Historical track record shows inconsistency and declining performance. Despite occasional beats, the trend is deteriorating.

Positives

Consistent earnings reporting across 25 quarters
Some quarters beat estimates (e.g., Q1 2025: +115.2%)

Watchpoints

Only 1 out of last 4 quarters beat estimates
Average earnings surprise of +25.1% but with high volatility
Persistent negative earnings and margins

Health

10/100

Financial health is dire. The Piotroski F-Score of 0 indicates systemic failure in profitability, liquidity, and leverage. No Altman Z-Score available raises bankruptcy risk concerns.

Positives

Extremely low debt/equity (0.06)
High current and quick ratios (18.80, 18.31)

Watchpoints

Piotroski F-Score of 0/9 (critical failure)
No Altman Z-Score available (risk of distress)
Negative ROE (-45.88%), ROA (-16.46%)

Dividend

0/100

No dividend policy exists; company is not generating profits to support payouts.

Positives

No standout positives identified.

Watchpoints

No dividend yield or payout
Payout ratio of 0.00%
Dividend strength of 0/100

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$4.27

Analyst Target

$5.75

Upside/Downside

+34.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ABUS and closest competitors.

Updated 2026-02-20

Company	5Y	3Y	1Y	6M	1M	1W
ABUS Arbutus Biopharma Corporation Primary	-0.5%	+54.7%	+24.1%	+18.9%	+3.1%	+7.3%
AHG Akso Health Group Peer	-40.6%	+246.5%	+7.2%	-12.9%	+8.0%	+4.9%
AMN AMN Healthcare Services, Inc. Peer	-72.8%	-78.8%	-26.3%	+3.5%	+28.0%	+7.7%
BGM BGM Group Ltd. Peer	-90.8%	-38.2%	-66.0%	-64.4%	-12.5%	0.0%
ABCL AbCellera Biologics Inc. Peer	-92.5%	-65.8%	-3.2%	-30.8%	-29.0%	-1.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-25.47

N/A

10.6

56.23

49.73

-23.68

$821.22M

Profitability

Profit margins and return metrics

Profit Margin -289.45%

Operating Margin -1567.68%

Gross Margin -98.86%

ROE -45.88%

ROA -16.46%

Growth

Revenue and earnings growth rates

Revenue Growth -60.5%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.06

Low debt

Current Ratio

18.8

Strong

Quick Ratio

18.31

Excellent

Cash/Share

$0.49

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-26

$N/A

2025-11-13

$-0.06

-21.8% surprise

2025-08-06

$0.01

+115.2% surprise

2025-05-14

$-0.18

-18.1% surprise

Healthcare Sector Comparison

Comparing ABUS against 146 companies in the Healthcare sector (11 bullish, 60 neutral, 75 bearish)

Return on Equity (ROE)

-45.88%

This Stock

-56.86%

Sector Avg

-19.3% (Below Avg)

Profit Margin

-289.45%

This Stock

-20.8%

Sector Avg

+1291.8% (Superior)

Debt to Equity

0.06

This Stock

2.68

Sector Avg

-97.8% (Less Debt)

Revenue Growth

-60.5%

This Stock

62.23%

Sector Avg

-197.2% (Slower)

Current Ratio

18.8

This Stock

3.45

Sector Avg

+444.9% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
ABUS Arbutus Biopharma Corporation	BEARISH	$821.22M	-	-45.9%	-289.4%	$4.27
AHG Akso Health Group	BEARISH	$818.31M	-	-80.3%	-%	$1.49
AMN AMN Healthcare Services, Inc.	BEARISH	$787.1M	-	-35.9%	-10.1%	$20.49
BGM BGM Group Ltd.	BEARISH	$746.32M	-	-16.5%	-26.3%	$3.72
ABCL AbCellera Biologics Inc.	BEARISH	$909.98M	-	-16.8%	-%	$3.04

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-02-02	ANDROSKI LINDSAY J.D.	Chief Executive Officer	Stock Award	28,000	-
2026-02-02	NGUYEN TUAN	Chief Financial Officer	Stock Award	73,500	-

Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

3 analysts

Chardan Capital

2025-11-14

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning ABUS from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V1 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends